Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
- Both studies fully recruited, with data from the Dengue [...]
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
· Emergex’s CD8+ T cell Adaptive Vaccine platform will now [...]
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding [...]
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus GalleryEmergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Abingdon, Oxon, UK, 22 February 2022 – Emergex Vaccines Holding [...]
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations GalleryEmergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
Emergex confirms that the viral peptides in its COVID-19 vaccine [...]
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
Synthetic vaccine designed to prime T-Cells to rapidly remove viral-infected [...]
Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants
The response to COVID-19 – a success story in vaccine [...]
Nature paper provides further evidence of the benefits of eliciting a T-Cell response for COVID-19
Abingdon, Oxon, UK, 11 November 2021 – Emergex Vaccines Holding [...]
Can One Vaccine Provide Immune Protection Against Multiple Pathogens?
Can One Vaccine Provide Immune Protection Against Multiple Pathogens? The [...]
T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why… GalleryT-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why…
T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why…
T-cell priming vaccines offer the potential to provide faster, broader [...]